{"id":4881,"date":"2019-10-28T13:23:42","date_gmt":"2019-10-28T18:23:42","guid":{"rendered":"https:\/\/calliercenter.utdallas.edu\/?post_type=doc&p=4881"},"modified":"2022-11-01T18:54:53","modified_gmt":"2022-11-01T23:54:53","slug":"section-9-sale-of-protected-health-information","status":"publish","type":"doc","link":"https:\/\/calliercenter.utdallas.edu\/doc\/section-9-sale-of-protected-health-information\/","title":{"rendered":"Section 9: Sale of Protected Health Information"},"content":{"rendered":"\n
Section 9: Sale of Protected Health Information<\/h2>\n\n\n\n
HIPAA defines the Sale of PHI as the disclosure of PHI in return for remuneration.<\/p>\n\n\n\n
UT Dallas shall not exchange PHI in return for direct or indirect remuneration without a signed authorization except:<\/p>\n\n\n\n
For purposes of public health<\/li>
Research permitted by HIPAA if the payment is a reasonable, cost-based fee to cover the cost of preparing and transmitting the PHI<\/li>
Treatment and payment<\/li>
Activities performed by a Business Associate if the payment is for the BA performance of such activities<\/li>
To provide access or an accounting of records to a patient<\/li>
As required by law<\/li>
As otherwise permitted under HIPAA where only a reasonable cost-based fee is paid<\/li><\/ul>\n\n\n\n
An authorization permitting a sale of PHI shall state that the sale will result in remuneration to UT Dallas.